Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

China Generic Drug Market & Registration (ANDA)

Date: 04.11.2021

Time: 10:00 AM CET

Price: Free of charge

On Thursday 4th November /  European time at 10am CET / Beijing Time 5pm, ELC will be hosting a webinar providing an overview of China Generic Drug Market & Registration (ANDA).

The speakers will be Sylvie Dinh, Head of Development Services; Sy Chyi Yeoh, Business Development Director from ELC Group.

We are going to take you through the following topics:

  • Market Overview & Access Pathways
  • Regulatory Framework & ANDA Submission
  • Clinical Study: Exemption & Requirements
  • Key Takeaways & Tips
  • Q&A

To participate, please fill in the form below. You will then receive an invitation to this webinar. Please note that the number of participants is limited.